Quickly find business customer service phone numbers

All Seattle Genetics support phone numbers are listed below, including customer service phone number(s), Headquarters support phone number(s), support phone number(s), support phone number(s), etc. You can also get Seattle Genetics support via email, social networks, help center, or directly check all the customer service contacts of Seattle Genetics.
Customer Service number
(Seagen International GmbH)
+4 131 528 0844
Customer Service number
(Seagen Canada)
+1 833 473 2436
Customer Service number
(Seagen France SAS)
+3 318 488 8069
Customer Service number
(Denmark)
+458 988 8353
Customer Service number
(Finland)
+35 875 325 2569
Customer Service number
(Norway)
+478 002 5129
Customer Service number
(Sweden)
+4 610 888 5437
Customer Service number
(UK)
+44 330 818 0490
Customer Service number
(Germany)
+49 893 803 6915
Customer Service number
(Austria)
+4 372 077 8105
Customer Service number
(Italy)
+39 028 295 2389
Customer Service number +327 848 2751
Customer Service number
(Luxembourg)
+3 522 786 7570
Customer Service number
(The Netherlands)
+3 120 241 9041
Customer Service number
(Spain)
+3 491 901 1012
Customer Service number
(Patient assistance)
+1 855 473 2873
[Headquarters] support phone number +1 425 527 4000

Seattle Genetics Overview

Targeting Cancer. Transforming Therapies. Seagen is where revolutionary science meets transformative cancer therapy. Seagen is committed to advancing late-stage clinical trials and expanding the development of its portfolio both in and outside the U.S. to better the health of people with cancer. We are dedicated to improving patient outcomes through advanced antibody-drug conjugate technology designed to deliver cell-killing agents directly to tumor cells. We are focused on discovering, developing and commercializing a new generation of transformative cancer medicines and empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Our industry-leading antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer. Using our proprietary technology, we are able to optimize each ADC to potentially improve outcomes for patients. ADCs are an integral part of the evolving cancer treatment paradigm with their specificity, stability and potency. We are expanding indications for three already approved cancer medicines and a pipeline of more than five novel targeted therapies at various stages of preclinical and clinical testing designed to address significant unmet medical needs.
Industry Biotechnology Research
Headquarters Bothell, Washington
Company size 1,001-5,000 employees
Website http://www.seagen.com

Top